Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns

CONCLUSIONS: Patients with HER2/CEP17≥2.0 and HER2 copy numbers ≥4.0 and <6.0 do not benefit to the same extent from current anti-HER2 therapies as FISH-positive patients with other patterns.PMID:38346865 | DOI:10.1136/jcp-2023-209069

Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Hong Lv Qian-Ming Bai Ming Li Meng-Yuan Cai Shu-Ling Zhou Yin Liu Zhong-Hua Wang Ruo-Hong Shui Hong-Fen Lu Xiao-Li Xu Bao-Hua Yu Xiao-Yu Tu Rui Bi Yu-Fan Cheng Xiao-Yan Zhou Zhi-Min Shao Wen-Tao Yang Source Type: research